RMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ResMed Inc (RMD) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown solid historical growth, near-term headwinds such as increased competition, bearish technical indicators, and mixed analyst sentiment suggest a cautious approach. Holding the stock or waiting for a more favorable entry point may be prudent.
The MACD histogram is positive at 0.26, indicating slight bullish momentum, but it is contracting. The RSI_6 is neutral at 38.949, showing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key support is at 186.635, and resistance is at 198.355. The stock is trading below its pivot point of 192.495, indicating weakness.
The company remains a global leader in the obstructive sleep apnea market, and analysts like JPMorgan and Citi maintain a positive medium- to long-term outlook. Historical earnings growth of 19% and revenue growth of 11% over the past three years are strong indicators of its past performance.
Morgan Stanley downgraded the stock due to potential competition from Philips' re-entry into the U.S. device market and the impact of GLP-1 weight-loss drugs. Bearish technical indicators and a lack of significant hedge fund or insider activity further dampen short-term prospects. Analyst price targets have been consistently lowered, reflecting cautious sentiment.
No financial data is available for the latest quarter. Historical data indicates strong growth trends, but future growth may be constrained by competitive pressures.
Analyst sentiment is mixed. While some firms like Citi and JPMorgan maintain a Buy or Overweight rating, others like Morgan Stanley and Baird have downgraded or lowered their price targets. The average price target has been revised downward across the board, reflecting near-term caution.
